The neuromuscular network for Canada


Linking clinicians and lab researchers for gene discovery: new publication on the Canadian Rare Disease Models and Mechanisms network

Over 70% of rare diseases are genetic in origin, but our understanding of the biological function of the 19,000 genes in the human genome is still often inadequate to reliably predict whether a defect in a particular gene is likely to cause a specific disease. Now that sequencing technologies that look for defects across the whole genome are becoming commonplace in diagnostics, clinicians attempting to diagnose their patients increasingly encounter the situation where they suspect a certain defect of being causative of the patient’s disease but do not have sufficient biological evidence to provide a certain diagnosis. To get from a “suspicion” about a defect in a gene not previously associated with a disease to biological proof of its effect requires extensive further research in cell and animal models, and this step is frequently one that the original clinician does not have the resources to perform.

The Canadian Rare Diseases Models and Mechanisms (RDMM) network was established to connect clinicians discovering new disease genes with Canadian scientists able to study equivalent genes and pathways in model organisms. It has developed a registry of more than 500 Canadian model organism scientists, representing expertise for over 7,500 human genes. To date, it has made 85 connections between clinicians and the scientists studying their genes of interest and has provided funding for 105 projects. These collaborations help confirm variant pathogenicity and unravel the molecular mechanisms of rare diseases, and also test novel therapies and lead to long-term collaborations. NMD4C collaborates with the RDMM network to ensure that neuromuscular clinicians with a gene of interest have the opportunity to seek scientists with the relevant expertise, as well as enabling NMD scientists to register with the network in order to facilitate future collaborations.

The story of the RDMM to date is nicely summarised in this new article by Boycott et al in the American Journal of Human Genetics:

Boycott KM, Campeau PM, Howley HE, Pavlidis P, Rogic S, Oriel C, Berman JN, Hamilton RM, Hicks GG, Lipshitz HD, Masson JY, Shoubridge EA, Junker A, Leroux MR, McMaster CR, Michaud JL, Turvey SE, Dyment D, Innes AM, van Karnebeek CD, Lehman A, Cohn RD, MacDonald IM, Rachubinski RA, Frosk P, Vandersteen A, Wozniak RW, Pena IA, Wen XY, Lacaze-Masmonteil T, Rankin C, Hieter P.
The Canadian Rare Diseases Models and Mechanisms (RDMM) Network: Connecting Understudied Genes to Model Organisms
Am J Hum Genet. 2020 Feb 6;106(2):143-152. doi: 10.1016/j.ajhg.2020.01.009.
PMID: 32032513


Read next...


Pulmonary Support for Myotonic Dystrophy Patients During COVID-19 Pandemic | Assistance Pulmonaire pour les Patients Atteints de Dystrophie Myotonique durant la Pandémie de COVID-19

Le français suit   New COVID-19-related guidance has been produced for people living with myotonic dystrophy who already use some respiratory support at home or who need it if they get sick. These devices are very important to keep you breathing well, but extra care needs to be taken to make sure they are kept…


COVID-19 and Neuromuscular Patients | La COVID-19 et les Patients Neuromusculaires

Last updated on March 26, 2020, at 8:30am Dernière mise à jour le 26 mars, 2020, 8h30   Download as a PDF Télécharger au format PDF   Le français suit   There is an abundance of information available on COVID-19, but little guidance specific to Canadians with neuromuscular disease (NMD), their families, and their caregivers.…

12 Lead Electrocardiogram Record Paper

New clinical care recommendations available for cardiologists treating adults with myotonic dystrophy

(le français suit) Cardiac complications may affect more than 50% of patients with myotonic dystrophy and occur in both myotonic dystrophy type 1 (DM1) and type 2 (DM2). Cardiac conduction system disturbances can have sudden and catastrophic presentations, but are often preventable through proper management. Cardiac surveillance of patients with myotonic dystrophy can therefore be…


New pan-Canadian neuromuscular network unites doctors, researchers and patients for better research and care

A new Canadian network for neuromuscular disease was launched today in Ottawa, the home of its coordination hub. NMD4C (NMD for Canada) received catalyst funding from the Canadian Institutes of Health Research and Muscular Dystrophy Canada to develop solutions that will enable healthcare professionals, researchers and patients to work together and share expertise. The network…

About us

Exciting job opportunities at the NMD4C coordination office

Do you have a passion for research and care in neuromuscular diseases and the difference it can make for Canadian patients? We want you!


Walk for Muscular Dystrophy announce dates and times across Canada

Muscular Dystrophy Canada (MDC) have announced the dates and times of their annual Walk for Muscular Dystrophy in more than 40 locations across Canada.

Sign up for our newsletter



World Muscle Society 2020

The 25th International Annual Congress of the World Muscle Society takes place from 30th September – 4th October 2020, in Halifax, Nova Scotia, Canada. The...

2020 NMD4C network meeting

We are co-locating our 2020 network meeting with the MDC 2020 conference at the Sheraton Centre Toronto hotel.

OttawaNMD 2021

Save the date for OttawaNMD 2021! The uOttawa Centre for Neuromuscular Disease will host the 6th Ottawa International Conference on Neuromuscular Disease and Biology in...